CC The Chemours Company

Chemical stocks are flashing some of the highest dividend yields in the sector right now, but the number your screener shows and the check you will actually receive are not the same thing, and the gap between them hides a story most investors have not noticed yet.

Investors need to pay close attention to CC stock based on the movements in the options market lately.

Investing.com -- Shares in Swiss chocolate maker Lindt & Sprüngli fell 7% on Tuesday after the company cut its full-year organic sales growth forecast to 0%-2% from 4%-6%, citing weaker demand in Germany, Switzerland and Austria following price increases and an unusually hot summer.

On September 9, 2026, Chemours, DuPont, and Corteva reached a settlement with North Carolina and 11 nearby local entities, agreeing to pay US$455 million over 15 years to resolve PFAS-related claims tied to Chemours’ Fayetteville Works facility and other contamination issues. The agreement not only clears a significant portion of Chemours’ legacy PFAS exposure but also introduces a shared, net-present-value framework under the companies’ existing US$4.00 billion cost-sharing cap, potentially...

On August 4, The Chemours Company (NYSE:CC) reported second-quarter results that read like two different companies fused. Net sales barely moved, adjusted profit shrank, and yet cash generation surged, and the loss on the bottom line narrowed sharply. For a stock trading under $40, that split personality is exactly what makes this quarter worth a […]

The Standard & Poor's 500 index slipped 0.8% this week, led to the downside by the health care and m

Payments will be made over 15 years to the state and 11 local communities excluded from a 2024 national water system settlement

The agreement resolves contaminant claims that Chemours’ Fayetteville Works facility released into the water and air. The three chemical giants also established a $135 million reserve fund.

The Chemours Company (NYSE:CC) shares traded higher Thursday after the company, DuPont, and Corteva reached a $455 million settlement resolving PFAS-related litigation in North Carolina. The gain came despite broader weakness, with the S&P 500 down 0.43% and the Materials sector falling 1.24%. Chemours’ Share Covered By Existing Accruals Chemours, DuPont de Nemours, Inc. (NYSE:DD), and Corteva, Inc. (NYSE:CTVA) reached a $455 million settlement with North Carolina and 11 local entities over PFAS

Chemours (NYSE:CC) shares rose 6% on Thursday after the company announced a settlement with the State of North Carolina and 11 local entities covering PFAS-related claims. The agreement resolves litigation concerning PFAS and other historical discharges from the Fayetteville Works facility, as well as claims involving alleged PFAS contamination unrelated to the site, including the use of aqueous film forming foam.

The companies settled with North Carolina and 11 communities that were excluded from a previous settlement over drinking-water toxins.

Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On August 10, Chemours (NYSE:CC) launched two new refrigerants, Opteon ZE and Opteon 515B, built specifically for stationary chillers that cool data centers, commercial buildings, and other facilities that cannot afford downtime. The announcement lands as data center operators everywhere are scrambling to keep pace with the heat that AI workloads generate, and Chemours is […]

TiO2 price pressure remains a headwind for Kronos Worldwide as lower selling prices offset volume gains and cost savings.

CC expands its low-GWP Opteon refrigerant portfolio to meet rising cooling needs from AI-driven data centers and support decarbonization goals.

Chemours stock has delivered a steep 48.2% decline over the past three years, yet its current valuation checks lean cheap. This sets up a contrast between past shareholder experience and what today’s price suggests. Recent headlines around refrigerant demand and new product launches add another layer for investors trying to judge whether the current level offers enough compensation for those risks. The share price is down 48.2% over three years, which signals that investors have been pricing...

Net sales fell 1% as pricing gains offset volume declines across segments.

CC's Q2 loss narrows, but lower volumes and sales weigh on results as it outlines a cautious Q3 outlook.

Chemours' (CC) recent financial results have cast less certainty on its medium-term growth, with its

CNC, DAR, GD, FCEL and CC stocks show how women-led companies are redefining growth with discipline, agility and results.

Chemours (NYSE:CC) said its second-quarter results reflected pricing gains, operational improvements and continued execution under its Pathway to Thrive strategy, while softer residential air-conditioning aftermarket demand weighed on sales in its Thermal & Specialized Solutions business. Presi

Chemours reported a lackluster second quarter, given the enthusiasm for its AI business heading in.

Chemours beats EBITDA expectations on pricing strength and APM growth, but cuts full-year guidance amid TSS aftermarket destocking and soft residential demand.

Moby summary of The Chemours Company's Q2 2026 earnings call

The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Chemours (CC) delivered earnings and revenue surprises of -2.33% and -4.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

KRO gains on healthy long-term TiO2 demand, higher sales volumes, and cost and pricing actions that could strengthen margins and support future growth.

Recent options activity in Chemours (CC) has drawn attention after the October 16, 2026 $6.00 call ranked among the most volatile equity contracts, suggesting traders are bracing for a sizeable move. See our latest analysis for Chemours. Those options signals sit against a weak short term backdrop for Chemours, with the 30 day share price return down 17.53% and the 90 day share price return down 40.10%, even as the year to date share price return is 35.59% and the 1 year total shareholder...

Eastman's Q2 earnings and sales top estimates as higher volumes and pricing drive double-digit profit growth.

IFF heads into Q2 earnings release with volume growth and productivity gains in focus as investors weigh cost pressures and mixed segment performance.

LyondellBasell topped Q2 earnings and sales estimates as solid margins, higher operating rates and supply disruptions lifted results despite market volatility.

LyondellBasell (LYB) delivered earnings and revenue surprises of +20.79% and +3.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TX heads into Q2 earnings with stronger margins, higher steel prices and demand recovery in Mexico likely to aid results amid headwinds from cost inflation.

Olin (OLN) delivered earnings and revenue surprises of 0.00% and +1.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Air Products beat fiscal Q3 earnings estimates as higher on-site volumes, pricing and currency lifted results, while sales narrowly missed estimates.

FMC's Q2 earnings beat estimates as cost gains offset weaker pricing and volumes. Revenues declined and 2026 sales guidance was cut.

LyondellBasell heads into Q2 earnings with tighter petrochemical supply, stronger pricing and a Bayport restart expected to support margins and profitability.

AEM beat Q2 earnings estimates as higher gold prices lifted profit, while updated production and spending guidance points to key shifts ahead.

LIN's Q2 earnings may have gained from resilient contracts and backlog, while weaker European industrial activity poses risks.

Investors need to pay close attention to CC stock based on the movements in the options market lately.

Albemarle (ALB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AU heads into Q2 results with expectations for sharply higher y/y earnings and sales as strong gold prices and production support performance.

DD is expected to have benefited from its innovation-driven investment, productivity actions and acquisitions amid cost pressures in Q2.

ASH's Q3 sales beat estimates as volume growth lifted all segments, but adjusted earnings missed and the company lowered its fiscal 2026 EPS growth outlook.

MEOH posted sharply higher Q2 earnings and revenue on stronger methanol prices and acquired assets, but both missed estimates.

Recently, analysts highlighted Chemours’ upcoming August 4 earnings report, flagging a positive Earnings ESP and a top Zacks Rank as indicators of a potential earnings beat and attractive valuation versus peers. This combination of a strong value score and increasingly upbeat earnings expectations has sharpened investor focus on Chemours’ fundamentals and its perceived undervaluation within the chemicals space. Next, we’ll examine how this heightened earnings optimism and value-focused...

CRS nears the Q4 earnings release with strong sales and EPS growth estimates as aerospace demand and productivity gains offset pressure in key end markets.

Chemours (CC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

NUE beat second-quarter earnings and sales estimates as higher prices and volumes lifted results, while it expects stronger consolidated earnings in Q3.